okt 17, 2018: 9:45 a.m. - 10:40 a.m.
As biomedical entrepreneurs seek to apply the newest biomedical research results to invest new treatment options that might help patients, a %u201Cvalley of death%u201D in funding availability continues to endure between the academic researcher and therapies ready to begin clinical trials. Over the past decade, publicly-financed organizations designed to bridge this %u201Cvalley%u201D with development grants have created a track record with notable success stories. Such non-dilutive funding sources reduce risks during the proof-of-concept stage and make investments more attractive to equity investors. Panelists in this session will explore the characteristics of academic spinouts that continued past the grant stage to attract major and repeated investments from venture capital as well as that demonstrated therapeutic progress.%uFFFD
Moderator: Simone Fishburn, PhD, Editor, BioCentury and BioCentury Innovations%uFFFD